PTPRC and neoplasm: Considering that tumor burden was related to a reduction in the percentage of the splenic B cell population (CD45+/B220+/CD19+), which was counterbalanced by cidofovir treatment of the first xenograft, we evaluated whether mature B cells were activated and differentiated into antibody-secreting plasma cells.